Moderna teams up with Recordati to commercialize rare disease therapy

Truvian Health bags FDA clearance for CBC on TruVerus System

TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample

Dr Reddys Laboratories consolidated Q3 FY26 PAT drops to Rs. 1209.8 Cr, expands global pipeline

The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025

Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator

This marks the second indication for which gumokimab has gained NDA review acceptance

Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries

Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally

AstraZeneca gains full global rights to AbelZeta’s CAR-T therapy in $630M deal

Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing

The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing

HRV Pharma & SMS LifeSciences form strategic partnership for orphan and niche APIs

AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder

Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector

Syngene locks in Bristol Myers Squibb alliance through 2035

The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle